Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein Kinase Inhibitors
Tumor Markers, Biological
MetadataShow full item record
CitationSustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia. 2010, 34 (7):e176-7 Leuk. Res.
- BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
- Authors: Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T
- Issue date: 2007 Dec 1
- Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.
- Authors: Barbany G, Höglund M, Simonsson B, Swedish CML Group
- Issue date: 2002 Aug 15
- Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
- Authors: Carella AM
- Issue date: 2007 Mar
- Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
- Authors: Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW
- Issue date: 2010 Apr 10
- Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
- Authors: Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A
- Issue date: 2005 Apr 15